According to National Cancer Institute, a part of the U.S. National Institutes of Health, acute myeloid leukemia is a type of cancer that affects the blood and bone marrow. It is characterized by overproduction of immature white blood cells, myeloblasts or leukemic blasts. These cells crowd the bone marrow, preventing it from making normal blood cells. They can also spill out into the blood stream and circulate around the body. Takeda Pharmaceutical Company Limited is in the process of developing, Alisertib, for the treatment of AML. It is an orally active, small-molecule inhibitor of the aurora A kinase. The aurora family of protein kinases is involved in the regulation of cell growth and proliferation, particularly in chromosome segregation and cytokinesis. The drug candidates of acute myeloid leukemia pipeline also contains Durvalumab, T cell-based immunotherapies and Vyxeos. Some of the key players operating in the acute myeloid leukemia therapeutics pipeline include Celgene Corporation, Medigene AG, Bristol-Myers Squibb, and Takeda Pharmaceutical Company Limited.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.